Demographic data of patients with PsA. Data are n (%) unless otherwise indicated.
| Age, yrs*, mean (± SD) | 59.5 (13.5) |
| Duration PsA, yrs*, mean (± SD) | 20.4 (11.1) |
| Duration PsO, yrs*, mean (± SD) | 31.1 (16.4) |
| BMI*, mean (± SD) | 27.7 (5.1) |
| Male | 234 (50.4) |
| Destructive/deforming disease | 233 (50.7) |
| bDMARD (ever) | 57 (12.4) |
| sDMARD (ever) | 312 (67.2) |
| Fulfilling CASPAR criteria | 418 (90.3) |
| Exclusive DIP joint disease according to Moll and Wright** | 3 (0.6) |
| Mono/oligoarthritis according to Moll and Wright** | 214 (46.1) |
| Polyarthritis, including arthritis mutilans (n = 8), according to Moll and Wright** | 197 (42.5) |
| Axial disease without peripheral joint involvement | 33 (7.1) |
| Axial and peripheral joint involvement | 46 (9.9) |
| Smoker (ever) | 248 (55.0) |
| Smoker (current) * | 69 (15.3) |
| Hypertension* | 205 (44.5) |
| Hyperlipidemia* | 71 (15.4) |
| Diabetes* | 58 (12.6) |
↵* At the end of the study (2011) or death.
↵** 1973 Moll and Wright criteria for PsA. PsA: psoriatic arthritis; PsO: psoriasis; BMI: body mass index; DAI: disease activity index; DMARD: disease-modifying antirheumatic drug; bDMARD: biological DMARD; sDMARD: synthetic DMARD; NSAID: nonsteroidal antiinflammatory drug; CASPAR: ClASsification for Psoriatic ARthritis (criteria); DIP: distal interphalangeal.